Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.44
-0.82 (-7.28%)
Oct 2, 2026, 3:54 PM EDT - Market open
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $8.97M in the quarter ending June 30, 2026, a decrease of -61.33%. This brings the company's revenue in the last twelve months to $28.73M, down -83.86% year-over-year. In the year 2025, Monte Rosa Therapeutics had annual revenue of $123.67M with 63.54% growth.
Revenue (ttm)
$28.73M
Revenue Growth
-83.86%
P/S Ratio
30.83
Revenue / Employee
$166,052
Employees
173
Market Cap
890.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 123.67M | 48.05M | 63.54% |
| Dec 31, 2024 | 75.62M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| Janux Therapeutics | 24.00M |
| Adlai Nortye Group | 18.06M |
| Aktis Oncology | 10.06M |
| SL Science Holding | 3.27M |
| Odyssey Therapeutics | 99.00K |
GLUE News
- 1 day ago - Monte Rosa Therapeutics Transcript: Study result - Transcripts
- 1 day ago - Monte Rosa Therapeutics Press release: Study result - Filings
- 1 day ago - Monte Rosa Therapeutics Slides: Study result - Filings
- 1 day ago - Monte Rosa announces data from GFORCE-1, plans for Phase 2 program of MRT-8102 - TheFly
- 1 day ago - Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk - GlobeNewsWire
- 1 day ago - Monte Rosa Therapeutics initiated with a Buy at H.C. Wainwright - TheFly
- 1 day ago - Monte Rosa Therapeutics to present results of MRT-8102 GFORCE-1 Phase 1 study - TheFly
- 1 day ago - Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk - GlobeNewsWire